{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:33:18Z","timestamp":1774031598626,"version":"3.50.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Gabapentin has increasingly been identified as a drug of abuse, especially when used concurrently with opioids. Rescheduling gabapentin as a Schedule V controlled substance may strengthen monitoring and prescribing restrictions. The purpose of this study was to characterize the impact of rescheduling gabapentin from a nonscheduled to a Schedule V substance in Virginia on discharge prescribing patterns in a health system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective, pre-post, multicenter chart review conducted at 4 sites. Data from 3 months before gabapentin rescheduling (prerescheduling group) and 3 months after gabapentin rescheduling (postrescheduling group) were evaluated. The primary outcome was the percentage of newly prescribed gabapentin prescriptions upon discharge, which was compared between the pre- and postrescheduling groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A similar percentage of gabapentin prescriptions were newly prescribed in the prerescheduling group as compared to the postrescheduling group (55.0% vs 50.0%, P = 0.479). Gabapentin prescribing characteristics did not differ between the groups for new gabapentin prescriptions (n = 55 in the prerescheduling group, n = 50 in the postrescheduling group). Concomitant discharge prescribing of benzodiazepines (5.5% vs 2.0%, P = 0.619) and opioids (45.5% vs 60.0%, P = 0.136) did not differ significantly between the postrescheduling group and prerescheduling group for new gabapentin prescriptions. However, fewer opioid prescriptions exceeded 90 daily morphine milligram equivalents (MME) in the postrescheduling group as compared to the prerescheduling group for new gabapentin prescriptions (36.0% vs 20.0%, P = 0.020).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Gabapentin prescribing practices did not differ before and after rescheduling of gabapentin as a controlled substance. There was a trend toward dosages with reduced daily MME for concomitant opioid prescriptions after rescheduling. However, additional investigation with larger studies over longer periods of time is needed to discover whether gabapentin rescheduling significantly changes prescribing practices.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxab293","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T09:29:22Z","timestamp":1626773362000},"source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of discharge prescribing after rescheduling of gabapentin as a controlled substance"],"prefix":"10.1093","author":[{"given":"Melody J","family":"Robbins","sequence":"first","affiliation":[{"name":"Chesapeake Regional Medical Center, Chesapeake, VA, and Department of Pharmacy, Sentara Norfolk General Hospital, Norfolk, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Floroff","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sentara Norfolk General Hospital, Norfolk, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Ingemi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sentara Norfolk General Hospital, Norfolk, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus C","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sentara Norfolk General Hospital, Norfolk, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"issue":"7","key":"2021072718595435400_CIT0001","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse, and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"issue":"4","key":"2021072718595435400_CIT0002","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"2021072718595435400_CIT0003","first-page":"246","article-title":"Trends in gabapentin prescribing in a commercially insured U.S. adult population, 2009-2016","volume":"26","author":"Pauly","year":"2020","journal-title":"J Manag Care Spec Pharm."},{"issue":"10","key":"2021072718595435400_CIT0004","doi-asserted-by":"crossref","first-page":"e1002396","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"issue":"7","key":"2021072718595435400_CIT0005","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A decade of gabapentinoid misuse: an analysis of the European Medicine Agency\u2019s \u2018suspected adverse drug reactions\u2019","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"issue":"5","key":"2021072718595435400_CIT0006","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain\u2014is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N Engl J Med."},{"issue":"5","key":"2021072718595435400_CIT0007","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.0003-2409.2001.02399.x","article-title":"Gabapentin: pharmacology and its use in pain management","volume":"57","author":"Rose","year":"2002","journal-title":"Anaesthesia."},{"issue":"6","key":"2021072718595435400_CIT0008","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3821\/145.6.cpj280","article-title":"Prescribing gabapentin off label: perspectives from psychiatry, pain and neurology specialists","volume":"145","author":"Fukada","year":"2012","journal-title":"Can Pharm J (Ott)"},{"key":"2021072718595435400_CIT0009","first-page":"1178221818801311","article-title":"Gabapentin for off-label use: evidence-based or cause for concern?","volume":"12","author":"Peckham","year":"2018","journal-title":"Subst Abuse"},{"issue":"4","key":"2021072718595435400_CIT0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.18553\/jmcp.2002.8.4.266","article-title":"Gabapentin use in a managed Medicaid population","volume":"8","author":"Hamer","year":"2002","journal-title":"J Manag Care Pharm"},{"issue":"9","key":"2021072718595435400_CIT0011","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"Radley","year":"2006","journal-title":"Arch Intern Med"},{"issue":"4","key":"2021072718595435400_CIT0012","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/phar.2096","article-title":"Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured U.S. population","volume":"38","author":"Peckham","year":"2018","journal-title":"Pharmacotherapy."},{"key":"2021072718595435400_CIT0013","author":"Board of Pharmacy, Virginia Department of Health Professions"},{"key":"2021072718595435400_CIT0014","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/RMHP.S168504","article-title":"Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance","volume":"11","author":"Peckham","year":"2018","journal-title":"Risk Manag Healthc Policy."},{"key":"2021072718595435400_CIT0015","author":"Centers for Disease Control and Prevention"},{"issue":"5","key":"2021072718595435400_CIT0016","first-page":"10.4088\/PCC.15r01821","article-title":"Gabapentin therapy in psychiatric disorders: a systematic review","volume":"17","author":"Berlin","year":"2015","journal-title":"Prim Care Companion CNS Disord."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab293\/39350613\/zxab293.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab293\/39350613\/zxab293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T19:00:09Z","timestamp":1627412409000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxab293\/6324303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxab293","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"article-number":"zxab293"}}